{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:20:05Z","timestamp":1770909605985,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014605","name":"Sage Therapeutics","doi-asserted-by":"publisher","award":["Sage Therapeutics"],"award-info":[{"award-number":["Sage Therapeutics"]}],"id":[{"id":"10.13039\/100014605","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["Biogen"],"award-info":[{"award-number":["Biogen"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00213-024-06687-6","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T04:01:51Z","timestamp":1726804911000},"page":"389-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of zuranolone on next-day simulated driving in healthy adults"],"prefix":"10.1007","volume":"242","author":[{"given":"Joi","family":"Dunbar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Vaudreuil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indrani","family":"Nandy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Ona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret K.","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"6687_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/jsr.12158","volume":"23","author":"T Akerstedt","year":"2014","unstructured":"Akerstedt T, Anund A, Axelsson J, Kecklund G (2014) Subjective sleepiness is a sensitive indicator of insufficient sleep and impaired waking function. J Sleep Res 23:240\u2013252. https:\/\/doi.org\/10.1111\/jsr.12158","journal-title":"J Sleep Res"},{"key":"6687_CR2","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/jcpt.13165","volume":"45","author":"J Caron","year":"2020","unstructured":"Caron J, Kaye R, Wessel T, Halseth A, Kay G (2020) An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine. J Clin Pharm Ther 45:774\u2013782. https:\/\/doi.org\/10.1111\/jcpt.13165","journal-title":"J Clin Pharm Ther"},{"key":"6687_CR3","unstructured":"Compton R, Berning A (2015) Drug and Alcohol Crash Risk [Traffic Safety Facts]: Research Note. National Highway Traffic Safety Administration. https:\/\/rosap.ntl.bts.gov\/view\/dot\/1993"},{"key":"6687_CR4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","volume":"78","author":"KM Deligiannidis","year":"2021","unstructured":"Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, Doherty J, Jonas J, Li S, Sankoh AJ, Silber C, Campbell AD, Werneburg B, Kanes SJ, Lasser R (2021) Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry 78:951\u2013959. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.1559","journal-title":"JAMA Psychiatry"},{"key":"6687_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1176\/appi.ajp.20220785","volume":"180","author":"KM Deligiannidis","year":"2023","unstructured":"Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, Bullock A, Kotecha M, Li S, Forrestal F, Rana N, Garcia M, Leclair B, Doherty J (2023) Zuranolone for the treatment of postpartum depression. Am J Psychiatry 180:668\u2013675. https:\/\/doi.org\/10.1176\/appi.ajp.20220785","journal-title":"Am J Psychiatry"},{"key":"6687_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.trf.2020.07.009","volume":"73","author":"S Depestele","year":"2020","unstructured":"Depestele S, Ross V, Verstraelen S, Brijs K, Brijs T, van Dun K, Meesen R (2020) The impact of cognitive functioning on driving performance of older persons in comparison to younger age groups: a systematic review. Transp Res Part F: Traffic Psychol Behav 73:433\u2013452. https:\/\/doi.org\/10.1016\/j.trf.2020.07.009","journal-title":"Transp Res Part F: Traffic Psychol Behav"},{"key":"6687_CR7","doi-asserted-by":"publisher","unstructured":"Dmitrienko A, D\u2019Agostino RB, Sr (2018) Multiplicity considerations in clinical trials. N Engl J Med 378:2115\u20132122. https:\/\/doi.org\/10.1056\/NEJMra1709701","DOI":"10.1056\/NEJMra1709701"},{"key":"6687_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40263-019-00605-7","volume":"33","author":"A Frieder","year":"2019","unstructured":"Frieder A, Fersh M, Hainline R, Deligiannidis KM (2019) Pharmacotherapy of postpartum depression: current approaches and novel drug development. CNS Drugs 33:265\u2013282. https:\/\/doi.org\/10.1007\/s40263-019-00605-7","journal-title":"CNS Drugs"},{"key":"6687_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540\u2013545. https:\/\/doi.org\/10.1093\/sleep\/14.6.540","journal-title":"Sleep"},{"key":"6687_CR10","doi-asserted-by":"publisher","first-page":"204512532110658","DOI":"10.1177\/20451253211065859","volume":"12","author":"Y Kaufman","year":"2022","unstructured":"Kaufman Y, Carlini SV, Deligiannidis KM (2022) Advances in pharmacotherapy for postpartum depression: a structured review of standard-of-care antidepressants and novel neuroactive steroid antidepressants. Ther Adv Psychopharmacol 12:20451253211065859. https:\/\/doi.org\/10.1177\/20451253211065859","journal-title":"Ther Adv Psychopharmacol"},{"key":"6687_CR11","unstructured":"Kay G (1995) CogScreen Overview. https:\/\/cogscreen.com\/Overview.aspx"},{"key":"6687_CR12","doi-asserted-by":"crossref","unstructured":"Kay G, Ahmad O, Brown T, Veit A (2013) Comparison of the MINISIM and STISIM driving simulators for the detection of impairment: an alcohol validation study. University of Iowa. https:\/\/pubs.lib.uiowa.edu\/driving\/article\/28488\/galley\/136780\/view\/","DOI":"10.17077\/drivingassessment.1487"},{"key":"6687_CR13","doi-asserted-by":"publisher","unstructured":"Kay GG, Hochadel T, Sicard E, Natarajan KK, Kim NN (2017) Next-day residual effects of flibanserin on simulated driving performance in premenopausal women. Hum Psychopharmacol 32. https:\/\/doi.org\/10.1002\/hup.2603","DOI":"10.1002\/hup.2603"},{"key":"6687_CR14","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1002\/sim.5384","volume":"31","author":"E Laska","year":"2012","unstructured":"Laska E, Meisner M, Wanderling J (2012) A maximally selected test of symmetry about zero. Stat Med 31:3178\u20133191. https:\/\/doi.org\/10.1002\/sim.5384","journal-title":"Stat Med"},{"key":"6687_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1365-2869.2009.00746.x","volume":"18","author":"TR Leufkens","year":"2009","unstructured":"Leufkens TR, Lund JS, Vermeeren A (2009) Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J Sleep Res 18:387\u2013396. https:\/\/doi.org\/10.1111\/j.1365-2869.2009.00746.x","journal-title":"J Sleep Res"},{"key":"6687_CR16","doi-asserted-by":"publisher","first-page":"946","DOI":"10.4088\/jcp.v69n0610","volume":"69","author":"R Machado-Vieira","year":"2008","unstructured":"Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA Jr (2008) Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 69:946\u2013958. https:\/\/doi.org\/10.4088\/jcp.v69n0610","journal-title":"J Clin Psychiatry"},{"key":"6687_CR17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/75761","volume":"3","author":"RM McKernan","year":"2000","unstructured":"McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, Garrett L, Bristow L, Marshall G, Macaulay A, Brown N, Howell O, Moore KW, Carling RW, Street LJ, Castro JL, Ragan CI, Dawson GR, Whiting PJ (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 3:587\u2013592. https:\/\/doi.org\/10.1038\/75761","journal-title":"Nat Neurosci"},{"key":"6687_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.5665\/SLEEP.1272","volume":"34","author":"MA Mets","year":"2011","unstructured":"Mets MA, de Vries JM, de Senerpont Domis LM, Volkerts ER, Olivier B, Verster JC (2011) Next-day effects of ramelteon (8\u00a0mg), zopiclone (7.5\u00a0mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. Sleep 34:1327\u20131334. https:\/\/doi.org\/10.5665\/SLEEP.1272","journal-title":"Sleep"},{"key":"6687_CR19","doi-asserted-by":"publisher","first-page":"e2732","DOI":"10.1002\/hup.2732","volume":"35","author":"EM Pearlman","year":"2020","unstructured":"Pearlman EM, Wilbraham D, Dennehy EB, Berg PH, Tsai M, Doty EG, Kay GG (2020) Effects of Lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol 35:e2732. https:\/\/doi.org\/10.1002\/hup.2732","journal-title":"Hum Psychopharmacol"},{"key":"6687_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/2042098615579314","volume":"6","author":"AA Simen","year":"2015","unstructured":"Simen AA, Gargano C, Cha JH, Drexel M, Bautmans A, Heirman I, Laethem T, Hochadel T, Gheyle L, Bleys K, Beals C, Stoch A, Kay GG, Struyk A (2015) A randomized, crossover, placebo-controlled clinical trial to assess the sensitivity of the CRCDS Mini-sim to the next-day residual effects of zopiclone. Ther Adv Drug Saf 6:86\u201397. https:\/\/doi.org\/10.1177\/2042098615579314","journal-title":"Ther Adv Drug Saf"},{"key":"6687_CR21","doi-asserted-by":"publisher","first-page":"e32745","DOI":"10.7759\/cureus.32745","volume":"14","author":"S Suryawanshi Ot, Pajai","year":"2022","unstructured":"Suryawanshi Ot, Pajai S (2022) A comprehensive review on postpartum depression. Cureus 14:e32745. https:\/\/doi.org\/10.7759\/cureus.32745","journal-title":"Cureus"},{"key":"6687_CR22","doi-asserted-by":"publisher","first-page":"e21355","DOI":"10.1016\/j.heliyon.2023.e21355","volume":"9","author":"JL Tapia","year":"2023","unstructured":"Tapia JL, Dunabeitia JA (2023) Driving safety: investigating the cognitive foundations of accident prevention. Heliyon 9:e21355. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21355","journal-title":"Heliyon"},{"key":"6687_CR23","unstructured":"US Food and Drug Administration (2017) Guidance for industry: evaluating drug effects on the ability to operate a motor vehicle. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/evaluating-drug-effects-ability-operate-motor-vehicle"},{"key":"6687_CR25","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.5665\/sleep.5168","volume":"38","author":"A Vermeeren","year":"2015","unstructured":"Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van Oers AC, Palcza J, Li X, Laethem T, Heirman I, Bautmans A, Troyer MD, Wrishko R, McCrea J (2015) On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40\u00a0mg: a study in non-elderly healthy volunteers. Sleep 38:1803\u20131813. https:\/\/doi.org\/10.5665\/sleep.5168","journal-title":"Sleep"},{"key":"6687_CR26","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00213-016-4375-x","volume":"233","author":"A Vermeeren","year":"2016","unstructured":"Vermeeren A, Vets E, Vuurman EF, Van Oers AC, Jongen S, Laethem T, Heirman I, Bautmans A, Palcza J, Li X, Troyer MD, Wrishko R, McCrea J, Sun H (2016) On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30\u00a0mg in healthy elderly. Psychopharmacology 233:3341\u20133351. https:\/\/doi.org\/10.1007\/s00213-016-4375-x","journal-title":"Psychopharmacology"},{"key":"6687_CR24","doi-asserted-by":"publisher","unstructured":"Vermeeren A, Jongen S, Murphy P, Moline M, Filippov G, Pinner K, Perdomo C, Landry I, Majid O, Van Oers ACM, Van Leeuwen CJ, Ramaekers JG, Vuurman E (2019) On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep 42. https:\/\/doi.org\/10.1093\/sleep\/zsy260","DOI":"10.1093\/sleep\/zsy260"},{"key":"6687_CR27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00213-011-2400-7","volume":"219","author":"JC Verster","year":"2012","unstructured":"Verster JC, Roth T (2012) Drivers can poorly predict their own driving impairment: a comparison between measurements of subjective and objective driving quality. Psychopharmacology 219:775\u2013781. https:\/\/doi.org\/10.1007\/s00213-011-2400-7","journal-title":"Psychopharmacology"},{"key":"6687_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/1573400054065613","volume":"1","author":"JC Verster","year":"2005","unstructured":"Verster JC, Veldhuijzen DS, Volkerts ER (2005) Is it safe to drive a car when treated with anxiolytics? Evidence from on-the-road driving studies during normal traffic. Curr Psychiatr Rev 1:215\u2013225. https:\/\/doi.org\/10.2174\/1573400054065613","journal-title":"Curr Psychiatr Rev"},{"key":"6687_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/157488611798280933","volume":"6","author":"JC Verster","year":"2011","unstructured":"Verster JC, Spence DW, Shahid A, Pandi-Perumal SR, Roth T (2011) Zopiclone as positive control in studies examining the residual effects of hypnotic drugs on driving ability. Curr Drug Saf 6:209\u2013218. https:\/\/doi.org\/10.2174\/157488611798280933","journal-title":"Curr Drug Saf"},{"key":"6687_CR29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ejphar.2014.10.032","volume":"753","author":"JC Verster","year":"2015","unstructured":"Verster JC, van de Loo AJ, Roth T (2015) Mirtazapine as positive control drug in studies examining the effects of antidepressants on driving ability. Eur J Pharmacol 753:252\u2013256. https:\/\/doi.org\/10.1016\/j.ejphar.2014.10.032","journal-title":"Eur J Pharmacol"},{"key":"6687_CR31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.4088\/jcp.v66n0405","volume":"66","author":"M Wingen","year":"2005","unstructured":"Wingen M, Bothmer J, Langer S, Ramaekers JG (2005) Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 66:436\u2013443. https:\/\/doi.org\/10.4088\/jcp.v66n0405","journal-title":"J Clin Psychiatry"},{"key":"6687_CR32","unstructured":"ZURZUVAE\u2122 PI (2024) Full prescribing information. Sage Therapeutics, Inc. and Biogen Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217369s001lbl.pdf"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06687-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-024-06687-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06687-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T08:47:53Z","timestamp":1738054073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-024-06687-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6687"],"URL":"https:\/\/doi.org\/10.1007\/s00213-024-06687-6","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]},"assertion":[{"value":"26 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and is consistent with Good Clinical Practice guidelines according to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Harmonized Tripartite Guideline, as well as all applicable regulatory requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Joi Dunbar, Carrie Vaudreuil, Indrani Nandy, and Victor Ona are employees of Sage Therapeutics, Inc., and may hold stock and\/or stock options.\u00a0Gaetano Morelli has no conflicts of interest to disclose. Rakesh Jain reports research funding from AbbVie, Lilly, Lundbeck, Otsuka, Pfizer, Shire, and Takeda and participation on advisory boards for Adamas Pharmaceuticals; Alkermes; Corium; Eisai; Janssen; Lilly; Lundbeck; Merck; Neos Therapeutics; Neurocrine Biosciences; Otsuka; Pamlab; Pfizer; Sage Therapeutics, Inc.; Shire; Sunovion; Supernus; Takeda; Teva Pharmaceuticals; and Usona. Rakesh Jain also reports honoraria for speakers\u2019 bureaus from AbbVie, Alkermes, Almatica, Axsome, Corium, Eisai, Intra-Cellular Therapies, Ironshore, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Otsuka, Pamlab, Pfizer, Shire, Sumitomo Pharma, Sunovion, Takeda, Tris Pharma, and Viatris and consulting fees from AbbVie; Acadia; Adamas Pharmaceuticals; Alfasigma; Alkermes; Almatica; Axsome; Biogen Inc.; Boehringer Ingelheim; Cingulate; Corium; Eisai; Evidera; Impel Pharmaceuticals; Janssen; Lilly; Lundbeck; Merck; Neos Therapeutics; Neurocrine Biosciences; Osmotica Pharmaceuticals; Otsuka; Pamlab; Pfizer; Sage Therapeutics, Inc.; Shire; Sumitomo Pharma; Sunovion; Supernus; Takeda; Teva Pharmaceuticals; Transcend Therapeutics; and Viatris.\u00a0Margaret K. Moseley and Seth Levin are employees of Biogen Inc. and may hold stock. Gary Kay is an employee of Cognitive Research Corporation and may hold stock.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}